Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis

被引:1
作者
Singh, Avinash Kumar [1 ,2 ]
Kumar, Anoop [4 ]
Agrawal, Narendra [2 ,3 ]
Bhurani, Dinesh [2 ,3 ]
Ahmed, Rayaz [2 ,3 ]
Sharma, Manju [5 ,6 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut Med, Div Pharmacol, New Delhi 110062, India
[2] Rajiv Gandhi Canc Inst, Res Ctr, Dept HematoOncol, Delhi 110085, India
[3] Rajiv Gandhi Canc Inst, Res Ctr, Sect 5, Delhi 110085, India
[4] Delhi Pharmaceut Sci & Res Univ DPSRU, Dept Pharmacol & Clin Res, Mehrauli-Badarpur Rd,Puspvihar Sect 3, New Delhi 110017, India
[5] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, New Delhi 110062, India
[6] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, New Delhi 110062, India
关键词
Hemoglobin; meta-analysis; blood cancer; tyrosine kinase inhibitors; incidence; imatinib; NEWLY-DIAGNOSED PATIENTS; SURVIVAL; MESYLATE; OUTCOMES; THERAPY; APLASIA; IMPACT; CML;
D O I
10.2174/2772432817666220315144253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear. Aim The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib. Methods The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31(st) July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3. Results A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns for the CML patients treated with Imatinib.
引用
收藏
页码:148 / 157
页数:10
相关论文
共 20 条
[1]  
Bauer Stephanie, 2021, J Adv Pract Oncol, V12, P521, DOI 10.6004/jadpro.2021.12.5.7
[2]   Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib [J].
Cesini, Laura ;
Carmosino, Ida ;
Breccia, Massimo ;
De Benedittis, Daniela ;
Mohamed, Sara ;
De Luca, Maria Lucia ;
Colafigli, Gioia ;
Molica, Matteo ;
Scalzulli, Emilia ;
Massaro, Fulvio ;
Mariggio, Elena ;
Rizzo, Lorenzo ;
Loglisci, Maria Giovanna ;
Scamuffa, Maria Cristina ;
Vozella, Federico ;
Diverio, Daniela ;
Mancini, Marco ;
Alimena, Giuliana ;
Foa, Robin ;
Latagliata, Roberto .
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) :660-664
[3]   European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia [J].
Hochhaus, A. ;
Baccarani, M. ;
Silver, R. T. ;
Schiffer, C. ;
Apperley, J. F. ;
Cervantes, F. ;
Clark, R. E. ;
Cortes, J. E. ;
Deininger, M. W. ;
Guilhot, F. ;
Hjorth-Hansen, H. ;
Hughes, T. P. ;
Janssen, J. J. W. M. ;
Kantarjian, H. M. ;
Kim, D. W. ;
Larson, R. A. ;
Lipton, J. H. ;
Mahon, F. X. ;
Mayer, J. ;
Nicolini, F. ;
Niederwieser, D. ;
Pane, F. ;
Radich, J. P. ;
Rea, D. ;
Richter, J. ;
Rosti, G. ;
Rousselot, P. ;
Saglio, G. ;
Saussele, S. ;
Soverini, S. ;
Steegmann, J. L. ;
Turkina, A. ;
Zaritskey, A. ;
Hehlmann, R. .
LEUKEMIA, 2020, 34 (04) :966-984
[4]   Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia [J].
Hochhaus, Andreas ;
Larson, Richard A. ;
Guilhot, Francois ;
Radich, Jerald P. ;
Branford, Susan ;
Hughes, Timothy P. ;
Baccarani, Michele ;
Deininger, Michael W. ;
Cervantes, Francisco ;
Fujihara, Satoko ;
Ortmann, Christine-Elke ;
Menssen, Hans D. ;
Kantarjian, Hagop ;
O'Brien, Stephen G. ;
Druker, Brian J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10) :917-927
[5]   Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience [J].
Kantarjian, H ;
Talpaz, M ;
O'Brien, S ;
Giles, F ;
Faderl, S ;
Verstovsek, S ;
Garcia-Manero, G ;
Shan, JQ ;
Rios, MB ;
Champlin, R ;
de Lima, M ;
Cortes, J .
CANCER, 2005, 103 (10) :2099-2108
[6]   Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib [J].
Latagliata, Roberto ;
Volpicelli, Paola ;
Breccia, Massimo ;
Vozella, Federico ;
Romano, Angela ;
Montagna, Chiara ;
Molica, Matteo ;
Finsinger, Paola ;
Carmosino, Ida ;
Serrao, Alessandra ;
Zacheo, Irene ;
Santopietro, Michelina ;
Salaroli, Adriano ;
Alimena, Giuliana .
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) :105-108
[7]   Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia A case report [J].
Li, Xiang ;
Cai, Sisi ;
Zhong, Zhaodong ;
Wang, Hongxiang ;
Wang, Li ;
You, Yong ;
Zhang, Min .
MEDICINE, 2020, 99 (09)
[8]   Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era [J].
Liu, Zhenyou ;
Shi, Yuye ;
Yan, Zhiling ;
He, Zhengmei ;
Ding, Banghe ;
Tao, Shandong ;
Li, Yunjie ;
Yu, Liang ;
Wang, Chunling .
HEMATOLOGY, 2020, 25 (01) :181-185
[9]   Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia [J].
Mabed, Mohamed ;
Elhefni, Ashraf M. ;
Damnhouri, Ghazi .
LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2310-2311
[10]   Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study [J].
Matti, Bassam Francis ;
Naji, Alaadin Sahham ;
Alwan, Alaa Fadhil .
TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (04) :387-393